MX2019003089A - Compuestos de microarn y metodos para modular la actividad de mir-21. - Google Patents

Compuestos de microarn y metodos para modular la actividad de mir-21.

Info

Publication number
MX2019003089A
MX2019003089A MX2019003089A MX2019003089A MX2019003089A MX 2019003089 A MX2019003089 A MX 2019003089A MX 2019003089 A MX2019003089 A MX 2019003089A MX 2019003089 A MX2019003089 A MX 2019003089A MX 2019003089 A MX2019003089 A MX 2019003089A
Authority
MX
Mexico
Prior art keywords
activity
mir
methods
compositions
modulating mir
Prior art date
Application number
MX2019003089A
Other languages
English (en)
Inventor
Bhat Balkrishen
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of MX2019003089A publication Critical patent/MX2019003089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)

Abstract

En la presente se describen composiciones y métodos para la inhibición de la actividad de miR-21. Las composiciones tienen determinados patrones de modificación de nucleósidos que proporcionan potentes inhibidores de la actividad de miR-21. Las composiciones pueden usarse para inhibir miR-21 y también para tratar enfermedades asociadas con la expresión anormal de miR-21, tal como fibrosis y cáncer.
MX2019003089A 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21. MX2019003089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US201161565779P 2011-12-01 2011-12-01

Publications (1)

Publication Number Publication Date
MX2019003089A true MX2019003089A (es) 2019-07-18

Family

ID=46025979

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2013012452A MX2013012452A (es) 2011-04-25 2012-04-25 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2022000212A MX2022000212A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2019003090A MX2019003090A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2019003089A MX2019003089A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2022006595A MX2022006595A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2013012452A MX2013012452A (es) 2011-04-25 2012-04-25 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2022000212A MX2022000212A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.
MX2019003090A MX2019003090A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006595A MX2022006595A (es) 2011-04-25 2013-10-23 Compuestos de microarn y metodos para modular la actividad de mir-21.

Country Status (30)

Country Link
US (7) US9181547B2 (es)
EP (3) EP3211082B1 (es)
JP (2) JP6320292B2 (es)
KR (2) KR20190063482A (es)
CN (3) CN113151272A (es)
AU (4) AU2012249851B2 (es)
BR (1) BR112013027187A2 (es)
CA (2) CA2833615C (es)
CL (1) CL2013003105A1 (es)
CO (1) CO6821889A2 (es)
CY (1) CY1120304T1 (es)
DK (2) DK3211082T3 (es)
EA (1) EA025894B1 (es)
ES (2) ES2621863T3 (es)
HK (1) HK1243130A1 (es)
HR (2) HRP20170557T2 (es)
HU (2) HUE031595T2 (es)
IL (3) IL229032B (es)
LT (2) LT3211082T (es)
MX (5) MX2013012452A (es)
MY (2) MY187685A (es)
NZ (1) NZ717921A (es)
PL (2) PL3211082T3 (es)
PT (2) PT3211082T (es)
RS (1) RS61775B1 (es)
SG (1) SG194636A1 (es)
SI (2) SI2702155T1 (es)
TW (2) TWI698445B (es)
UA (1) UA115652C2 (es)
WO (1) WO2012148952A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
SG194636A1 (en) 2011-04-25 2013-12-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
WO2013153082A1 (en) * 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
EP2841579B1 (en) * 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
KR20150083920A (ko) 2012-11-15 2015-07-20 로슈 이노베이션 센터 코펜하겐 에이/에스 항 apob 안티센스 접합체 화합물
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
WO2015061536A1 (en) * 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3684949B1 (en) 2017-09-22 2024-04-17 University of Washington In situ combinatorial labeling of cellular molecules
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
CA3099698A1 (en) 2018-05-08 2019-11-14 Charles R. ALLERSON Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP1430128B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
EP1931780B1 (en) * 2005-08-29 2016-01-06 Regulus Therapeutics Inc. Antisense compounds having enhanced anti-microrna activity
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
MY162210A (en) * 2006-04-03 2017-05-31 Roche Innovation Ct Copenhagen As Pharmaceutical composition
MX2008012219A (es) * 2006-04-03 2008-10-02 Santaris Pharma As Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
US8906870B2 (en) 2006-10-09 2014-12-09 Julius-Maximilians-Universitaet Wuerzberg MicroRNA (miRNA) for the diagnosis and treatment of heart diseases
EP2104735A2 (en) 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
EP2118118B1 (en) 2007-01-19 2017-09-27 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US20100261175A1 (en) 2007-06-15 2010-10-14 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
MY156951A (en) * 2007-10-04 2016-04-15 Santaris Pharma As Micromirs
AU2008318778B2 (en) * 2007-10-29 2014-10-02 Regulus Therapeutics Inc. Targeting microRNAs for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US8361980B2 (en) 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
EP2401405A4 (en) * 2009-02-26 2013-10-16 Univ Ohio State Res Found MICROARN IN NON-SMOKERS AND METHODS AND RELATED MATERIALS
BRPI1010885A2 (pt) * 2009-06-08 2015-09-22 Miragen Therapeutics motivos de modificação química para inibidores mirna e miméticos.
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
SG194636A1 (en) * 2011-04-25 2013-12-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
EP2841579B1 (en) 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
EP3354734B1 (en) 2012-06-21 2020-06-10 Miragen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
EP2900822B1 (en) 2012-09-26 2021-11-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
EA025894B1 (ru) 2017-02-28
EA201391492A1 (ru) 2014-04-30
BR112013027187A2 (pt) 2017-06-06
US20200291400A1 (en) 2020-09-17
AU2012249851B2 (en) 2017-06-08
US20120270928A1 (en) 2012-10-25
KR102055172B1 (ko) 2020-01-23
EP2702155A1 (en) 2014-03-05
AU2012249851A1 (en) 2013-10-31
LT3211082T (lt) 2021-05-10
HUE054129T2 (hu) 2021-08-30
JP2014518619A (ja) 2014-08-07
CY1120304T1 (el) 2019-07-10
US8912161B2 (en) 2014-12-16
HRP20210616T1 (hr) 2021-05-28
US9181547B2 (en) 2015-11-10
HUE031595T2 (en) 2017-07-28
US20140329887A1 (en) 2014-11-06
JP6320292B2 (ja) 2018-05-09
MX2013012452A (es) 2014-11-21
CA3165397A1 (en) 2012-11-01
NZ717921A (en) 2017-09-29
TW201811812A (zh) 2018-04-01
SI3211082T1 (sl) 2021-08-31
JP2018121646A (ja) 2018-08-09
AU2022203067A1 (en) 2022-05-26
CN103620035A (zh) 2014-03-05
ES2621863T3 (es) 2017-07-05
CN103620035B (zh) 2021-04-23
PT3211082T (pt) 2021-04-28
IL229032A0 (en) 2013-12-31
IL229032B (en) 2021-01-31
US9790496B2 (en) 2017-10-17
CA2833615A1 (en) 2012-11-01
US20180155719A1 (en) 2018-06-07
SI2702155T1 (sl) 2017-07-31
WO2012148952A1 (en) 2012-11-01
IL266529A (en) 2019-07-31
ES2868950T3 (es) 2021-10-22
LT2702155T (lt) 2017-05-10
EP3211082B1 (en) 2021-02-17
PL3211082T3 (pl) 2021-08-02
KR20140033062A (ko) 2014-03-17
TWI607016B (zh) 2017-12-01
HK1243130A1 (zh) 2018-07-06
US20140107183A1 (en) 2014-04-17
NZ616748A (en) 2016-03-31
CL2013003105A1 (es) 2014-08-01
RS61775B1 (sr) 2021-05-31
MX2022000212A (es) 2022-04-01
MY175336A (en) 2020-06-19
EP2702155B9 (en) 2020-01-01
HRP20170557T2 (hr) 2020-02-21
US20220098583A1 (en) 2022-03-31
MX2022006595A (es) 2022-07-01
KR20190063482A (ko) 2019-06-07
CN113151272A (zh) 2021-07-23
CN113249381A (zh) 2021-08-13
UA115652C2 (uk) 2017-12-11
EP2702155B1 (en) 2017-02-01
MX2019003090A (es) 2019-07-18
PL2702155T3 (pl) 2017-09-29
AU2020201403A1 (en) 2020-03-12
US20160138016A1 (en) 2016-05-19
AU2017219156A1 (en) 2017-09-21
EP3211082A1 (en) 2017-08-30
IL273381A (en) 2020-05-31
MY187685A (en) 2021-10-11
AU2012249851A8 (en) 2013-11-14
CA2833615C (en) 2022-08-30
DK3211082T3 (da) 2021-05-10
TWI698445B (zh) 2020-07-11
AU2017219156B2 (en) 2020-01-02
TW201300404A (zh) 2013-01-01
CO6821889A2 (es) 2013-12-31
EP3933040A1 (en) 2022-01-05
ES2621863T9 (es) 2020-02-13
PT2702155T (pt) 2017-04-03
DK2702155T3 (en) 2017-05-01
SG194636A1 (en) 2013-12-30
HRP20170557T1 (hr) 2017-06-16

Similar Documents

Publication Publication Date Title
PH12014502387A1 (en) Microrna compounds and methods for modulating mir-21 activity
MX2019003090A (es) Compuestos de microarn y metodos para modular la actividad de mir-21.
AU2018236800B2 (en) DNA-PK inhibitors
MX2014013752A (es) Inhibidores de nampt.
PH12014502513A1 (en) Nampt inhibitors
SG190819A1 (en) Nampt and rock inhibitors
PH12015500260A1 (en) Neprilysin inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MY177344A (en) Compounds and their methods of use
GB201103062D0 (en) Method
MX343753B (es) Inhibidores de neprilisina.
MX348311B (es) Inhibidores nampt.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
PH12016501462A1 (en) Neprilysin inhibitors
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
IN2015DN01151A (es)
MX348024B (es) Compuestos de adamantilo.
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
TN2014000401A1 (en) Microrna compounds and methods for modulating mir-21 activity
MX2014002343A (es) Inhibidores de parp.